US free trade deals raise drug prices, Oxfam claims

8 April 2007

International antiglobalization group Oxfam has launched a campaign to persuade the US Congress to force changes on proposed free trade agreements between the USA and four other countries. Oxfam claims that the deals have caused drug prices in Jordan to rise 20%, six times above levels in Egypt.

The International Polcy Network, a UK-based think-tank, said that, "while prices may go up in the short-term, the intellectual property provisions in FTAs mean that more research-based companies will enter local markets, leading to increased price competition in the future. This will have a long-term benefit for patients."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight